← Markets

Pediatrix Medical Group, Inc.

MD · NYSE

Market closed$26.13$-0.210000 (-0.80%)After hours $26.10 · -0.11%

Key statistics

Previous close$26.34
Open$26.64
Day high$26.76
Day low$25.96
52-week high$27.94
52-week low$11.84
Market cap2.15B
Volume414.18K
Average volume838.96K
P/E ratio12.21
Forward P/E9.57
EPS2.14
Dividend yield0.00%

Market context

Why it moved

MD shares edged lower amid broad market caution and a lack of company-specific catalysts, with the modest decline likely reflecting routine profit-taking and sector-wide pressure rather than any major news event.

MoomooMarketbeatThebaynetMurthyMarketbeat

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026Pediatrix Medical Group edged lower, giving back some of the prior session's sharp 7%+ gain that followed the company's proactive Q2 business update. On July 15, Pediatrix distinguished itself from troubled sector peers by confirming its payor mix remained stable and reaffirming full-year 2026 Adjusted EBITDA guidance of $280–$300 million — a notable contrast to peers like UnitedHealth, Elevance, and HCA, which flagged ACA and Medicaid enrollment declines and rising medical costs. Analysts at Truist raised their price target to $28 from $23 (maintaining Hold), while Dimensional Fund Advisors disclosed a new 5.1% passive stake, adding institutional credibility. However, valuation debate is intensifying after a 105% one-year total return, with analyst consensus fair value around $23.17 suggesting the stock may be pricing in the good news ahead of Q2 earnings on August 4.

-0.7973

July 16, 2026Pediatrix Medical Group gained after the company issued a reassuring Q2 update confirming stable payor mix and reaffirming its full-year 2026 Adjusted EBITDA guidance of $280–$300 million — directly contrasting sector peers reporting unfavorable utilization and reimbursement shifts. The positive read-through from UnitedHealth Group's blowout Q2 earnings beat and raised guidance added a tailwind for the healthcare services space, while Truist Securities raised its price target on MD to $28 (maintaining Hold). Shares advanced roughly 1.78%, extending yesterday's 7.3% surge, with Dimensional Fund Advisors also disclosing a fresh 5.1% passive stake in the company.

1.7774

July 15, 2026Pediatrix Medical Group surged after issuing a rare mid-quarter business update confirming its payor mix remained stable and unchanged amid widespread industry concerns about unfavorable reimbursement shifts — a direct contrast to peers like HCA Healthcare and Universal Health Services, which have flagged rising uninsured patients and labor cost pressures. The company simultaneously reaffirmed its full-year 2026 Adjusted EBITDA guidance of $280–$300M, reassuring investors that its physician services model is insulated from the sector headwinds weighing on hospital operators. Truist Securities raised its price target to $28, and with 4 analysts recently revising estimates upward, the stock stands out as a defensive bright spot in a volatile healthcare landscape.

7.3414

July 14, 2026Pediatrix Medical Group tumbled nearly 8% as sector headwinds intensified following HCA Healthcare's preliminary Q2 warning that uninsured volume increases would weigh $400M on pre-tax income and that ACA exchange disruptions would exceed $1B in 2026—a signal of broader pressure on healthcare providers. Adding to the sector drag, Universal Health Services fell roughly 7% on similar concerns, while the healthcare facilities industry broadly faced selling pressure. Against this backdrop, Truist Securities maintained its Hold rating on Pediatrix but raised its price target from $23 to $28, offering limited support as the stock closed well below that revised target.

-7.7659

July 10, 2026Pediatrix Medical Group declined after analysts flagged valuation concerns, with consensus fair value estimates of $23.17 sitting well below the current trading price following a remarkable year-to-date gain of ~29% and a 1-year return exceeding 100%. Recent inclusion in the Russell 2000 Defensive and Russell 2000 Value-Defensive indexes drew index fund attention, but analyst commentary increasingly questions whether the rerating has run its course — particularly as the stock's P/E of ~12.6x, while below peer averages, trades at a premium to the $23.17 fair value target raised from $21.33 on July 9.

-2.4146

July 10, 2026Pediatrix Medical Group edged up modestly, outperforming the broader healthcare sector (XLV was roughly flat in after-hours) amid a volatile macro backdrop driven by renewed U.S.-Iran tensions and oil price surges. The stock is riding strong recent momentum — up over 21% in the past 30 days and nearly 29% year-to-date — following its recent addition to the Russell 2000 Defensive and Russell 2000 Value-Defensive indexes, which has drawn incremental institutional attention. Investors are now weighing a valuation debate: the stock trades at a discounted 12.6x P/E vs. peers at 26.6x, but a DCF-based fair value estimate pegs it near $21, raising questions about whether the sharp rerating has run ahead of fundamentals.

0.4853

July 8, 2026Pediatrix Medical Group closed essentially unchanged, holding near the $26.85 level, even as broader markets faced a risk-off session driven by President Trump declaring the U.S.-Iran interim peace deal 'over,' sending oil prices surging over 5% and pressuring equities. The stock's resilience reflects a broader healthcare sector rotation, with XLV logging strong recent performance—up 6.6% in June and leading S&P 500 sectors. Adding to investor attention, Pediatrix was recently added to the Russell 2000 Defensive and Russell 2000 Value-Defensive indexes, following a 28.65% YTD gain and a 1-year return exceeding 100%, though some valuation models now flag the stock as stretched above a $21.33 fair value estimate.

-0.2235

July 7, 2026Pediatrix Medical Group declined nearly 2% as broader U.S. equities faced headwinds, with the S&P 500 retreating amid rising Treasury yields — the 30-year topping 5% — and geopolitical uncertainty surrounding the NATO Summit. The notable development for Pediatrix specifically was its addition to the Russell 2000 Defensive Index and Russell Defensive Indexes, a classification that underscores its positioning as a defensive play within healthcare. While the healthcare sector broadly has been outperforming — XLV near its 52-week high following back-to-back market-leading weeks — Pediatrix lagged, likely reflecting the index inclusion question of whether the defensive premium is already priced in.

-1.9715

Yahoo Finance UK · July 17, 2026Is Pediatrix Medical Group (MD) Overvalued As It Reaffirms Its 2026 EBITDA Outlook?Zacks Investment Research · July 17, 2026Pediatrix Medical Q1 Earnings Beat Estimates on Same-Unit StrengthYahoo! Finance Canada · July 16, 2026Pediatrix Medical Group Provides Second Quarter UpdateGuruFocus · July 16, 2026Pediatrix Medical (MD) Maintains Stable Q2 Trends Amid Market ShGuruFocus · July 16, 2026A Look at Pediatrix Medical Group Inc (MD) After 7.3% Gain -- GF Value $13.18 vs Price $25.88Simply Wall Street · July 16, 2026Pediatrix Medical Group (MD) Reaffirms Outlook Following Stable Payor Mix, Is The Strength Already Priced In?Investing.com South Africa · July 15, 2026Pediatrix reaffirms 2026 outlook amid stable payor trends By Investing.comgrafa.com · July 15, 2026Pediatrix reaffirms $280–$300 million EBITDA outlook
Mt Newswire · July 15, 2026Pediatrix Medical Group Reiterates 2026 Adjusted EBITDA Outlook
Benzinga · July 15, 2026Pediatrix Reports Q2 Payor Mix Remains Stable, No Material Changes In Net Revenue Trends; Reaffirms FY26 Adj EBITDA Outlook Of $280M-$300M
Benzinga · July 14, 2026Truist Securities Maintains Hold on Pediatrix Medical Group, Raises Price Target to $28
Mt Newswire · July 14, 2026Truist Raises Price Target on Pediatrix Medical Group to $28 From $23, Keeps Hold Rating
Benzinga · June 30, 2026Under the Radar: Five Small-Cap Stocks Wall Street Is Missing
Benzinga · June 3, 2026Pediatrix Medical Group Publishes New Research On Probiotic Use And Necrotizing Enterocolitis In Preterm Infants
Benzinga · May 12, 2026UBS Maintains Neutral on Pediatrix Medical Group, Raises Price Target to $25
Mt Newswire · May 12, 2026UBS Adjusts Price Target on Pediatrix Medical to $25 From $22, Maintains Neutral Rating

Peers

S&P 500SPX · $7,457.69-1.01%Tenet Healthcare CorporationTHC · $194.91-2.15%HCA Healthcare, Inc.HCA · $371.18-3.77%Universal Health Services, Inc.UHS · $151.16-1.55%DaVita Inc.DVA · $236.97+1.26%Chemed CorporationCHE · $510.03+1.70%CorVel CorporationCRVL · $61.70-0.88%AMN Healthcare Services, Inc.AMN · $35.00+2.28%Cross Country Healthcare, Inc.CCRN · $13.240.00%Privia Health Group, Inc.PRVA · $26.90-1.18%NeoGenomics, Inc.NEO · $14.61-1.55%Brookdale Senior Living Inc.BKD · $15.01-1.77%